Novel Intravitreal Injections: Faricimab and Aflibercept 8mg for the Treatment of Retinal Diseases

Opinion
Video

Panelists discuss how novel intravitreal agents faricimab and high-dose aflibercept 8mg offer potential advantages in treating retinal diseases through their extended durability and dual mechanism of action.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
2 experts in this video
2 experts in this video
Related Content
Zeteo Biomedical receives new EU and US patents for its drug delivery technologies

Zeteo Biomedical receives new EU and US patents for its drug delivery technologies

Kassi Filkins
June 11th 2025
Article

ZTech-L and ZTech-P, as part of the ZTech portfolio, supports administering therapeutics in both liquid and dry powder formulations

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

Two business people in suits shake hands in front of a European Union flag. Concept image for Optegra and EssilorLuxottica acquisition, European expansion, expand into new areas of medical technology. Image credit: ©New Africa – stock.adobe.com

EssilorLuxottica acquires Optegra clinics with support from MidEuropa

Hattie Hayes
May 30th 2025
Article

The Optegra platform currently operates in the Czech Republic, the Netherlands, Poland, Slovakia and the United Kingdom

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

Isarna Therapeutics shares positive results from Phase 2 BETTER trial

Isarna Therapeutics shares positive results from Phase 2 BETTER trial

Sydney M Crago
May 7th 2025
Article
An image of Salt Lake City. Historic downtown area. Concept image for 2025 Association for Research in Vision and Ophthalmology (ARVO). Image credit: ©pabrady63 – stock.adobe.com

Editorial Advisory Board members bring research findings to ARVO

Sydney M Crago
May 5th 2025
Article

Members of the Ophthalmology Times Europe, Ophthalmology Times and Modern Retina editorial advisory boards are present and presenting at the 2025 ARVO meeting

© 2025 MJH Life Sciences

All rights reserved.